A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
Clinical trial NCT04056117 · COMPLETED
Trial details
- NCT number
- NCT04056117
- Sponsor
- LimmaTech Biologics AG
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-02
- Primary completion
- 2022-09-01
- Enrollment
- 597
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.